Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.597
-0.053 (-3.21%)
Aug 11, 2025, 10:48 AM - Market open
Oncternal Therapeutics Employees
Quince Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 4 or 12.50% compared to the previous year.
Employees
36
Change (1Y)
4
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,686,361
Market Cap
85.64M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36 | 4 | 12.50% |
Dec 31, 2023 | 32 | 11 | 52.38% |
Dec 31, 2022 | 21 | -34 | -61.82% |
Dec 31, 2021 | 55 | 17 | 44.74% |
Dec 31, 2020 | 38 | 15 | 65.22% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
QNCX News
- 4 days ago - Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP - Business Wire
- 26 days ago - Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia - Business Wire
- 4 weeks ago - Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board - Business Wire
- 6 weeks ago - Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference - Business Wire
- 7 weeks ago - Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities - Business Wire
- 2 months ago - Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities - Business Wire
- 2 months ago - Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia - Business Wire
- 3 months ago - Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026 - Seeking Alpha